These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1041 related items for PubMed ID: 34879870

  • 1. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD, Bai WQ, Zhai XT, Sun LP, Zhen YS, Li ZR, Miao QF.
    Mil Med Res; 2021 Dec 09; 8(1):63. PubMed ID: 34879870
    [Abstract] [Full Text] [Related]

  • 2. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY, Wang R, Jin J, Liu XJ, Cui AL, Sun LQ, Li YP, Li Y, Wang YC, Zhen YS, Miao QF, Li ZR.
    Mol Oncol; 2019 Feb 09; 13(2):246-263. PubMed ID: 30372581
    [Abstract] [Full Text] [Related]

  • 3. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z, Wang M, Yu D, Luo W, Fang J, Huang C, Yao X.
    Cancer Chemother Pharmacol; 2019 Jul 09; 84(1):61-72. PubMed ID: 31037333
    [Abstract] [Full Text] [Related]

  • 4. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
    Suthe SR, Yao HP, Weng TH, Wang MH.
    Curr Cancer Drug Targets; 2023 Jul 09; 23(2):103-117. PubMed ID: 36028965
    [Abstract] [Full Text] [Related]

  • 5. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR, Yao HP, Weng TH, Hu CY, Feng L, Wu ZG, Wang MH.
    Mol Cancer Ther; 2018 Dec 09; 17(12):2654-2664. PubMed ID: 30275241
    [Abstract] [Full Text] [Related]

  • 6. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y, Hu S, Chen Y, Zhang X, Gao H, Tian J, Chen J.
    Phytomedicine; 2023 Sep 09; 118():154924. PubMed ID: 37393829
    [Abstract] [Full Text] [Related]

  • 7. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 8. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS, Anstine LJ, Finke VS, Bryson BL, Webb BM, Weber-Bonk KL, Seachrist DD, Majmudar PR, Keri RA.
    Breast Cancer Res; 2020 Jun 18; 22(1):66. PubMed ID: 32552913
    [Abstract] [Full Text] [Related]

  • 9. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
    Adinew GM, Messeha SS, Taka E, Badisa RB, Antonie LM, Soliman KFA.
    Nutrients; 2022 May 19; 14(10):. PubMed ID: 35631261
    [Abstract] [Full Text] [Related]

  • 10. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.
    Ganesan K, Xu C, Wu J, Du B, Liu Q, Sui Y, Song C, Zhang J, Tang H, Chen J.
    Sci China Life Sci; 2024 Sep 19; 67(9):1849-1866. PubMed ID: 38900236
    [Abstract] [Full Text] [Related]

  • 11. Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling.
    Gautam J, Banskota S, Regmi SC, Ahn S, Jeon YH, Jeong H, Kim SJ, Nam TG, Jeong BS, Kim JA.
    Mol Cancer; 2016 Nov 21; 15(1):75. PubMed ID: 27871326
    [Abstract] [Full Text] [Related]

  • 12. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN, Kim S, Boerner JL, Viola NT.
    Breast Cancer Res; 2020 Apr 15; 22(1):37. PubMed ID: 32295603
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
    Elkhalifa D, Siddique AB, Qusa M, Cyprian FS, El Sayed K, Alali F, Al Moustafa AE, Khalil A.
    Eur J Med Chem; 2020 Feb 01; 187():111954. PubMed ID: 31838326
    [Abstract] [Full Text] [Related]

  • 14. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
    Li HC, Xia ZH, Chen YF, Yang F, Feng W, Cai H, Mei Y, Jiang YM, Xu K, Feng DX.
    Cell Physiol Biochem; 2017 Feb 01; 43(5):1829-1840. PubMed ID: 29050003
    [Abstract] [Full Text] [Related]

  • 15. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
    Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, Mehta RG.
    PLoS One; 2013 Feb 01; 8(6):e65113. PubMed ID: 23762292
    [Abstract] [Full Text] [Related]

  • 16. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
    Zhang C, Sheng W, Al-Rawe M, Mohiuddin TM, Niebert M, Zeppernick F, Meihold-Heerlein I, Hussain AF.
    Int J Mol Sci; 2022 May 30; 23(11):. PubMed ID: 35682800
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC.
    Mol Cancer Ther; 2014 Feb 30; 13(2):316-28. PubMed ID: 24337110
    [Abstract] [Full Text] [Related]

  • 18. 18F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer.
    Liu H, Sun H, Zhang B, Liu S, Deng S, Weng Z, Zuo B, Yang J, He Y.
    Breast Cancer; 2020 May 30; 27(3):372-380. PubMed ID: 31781983
    [Abstract] [Full Text] [Related]

  • 19. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
    Li Z, Wang M, Yao X, Luo W, Qu Y, Yu D, Li X, Fang J, Huang C.
    Target Oncol; 2019 Feb 30; 14(1):93-105. PubMed ID: 30635821
    [Abstract] [Full Text] [Related]

  • 20. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov 30; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.